CLINICAL TRIALS PROFILE FOR SULFISOXAZOLE

All Clinical Trials for SULFISOXAZOLE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Fundação de Amparo à Pesquisa do Estado de São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02017197 ↗	Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil	Completed	Federal University of São Paulo	Phase 4	2014-08-01	The purpose of this study is to assess whether the switch from branded to generic warfarin or between different generic warfarin tablets may cause fluctuation in the results of coagulation tests (International Normalized Rate, acronym INR) in patients, thus predisposing them to unnecessary risks.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	James Graham Brown Cancer Center	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	University of Louisville	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	Julio Ramirez	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.

Clinical Trial Conditions for SULFISOXAZOLE

Condition Name

Condition Name for SULFISOXAZOLE
Intervention	Trials
Osteomyelitis	1
Atrial Fibrillation	1

Condition MeSH

Condition MeSH for SULFISOXAZOLE
Intervention	Trials
Osteomyelitis	1
Atrial Fibrillation	1

Clinical Trial Locations for SULFISOXAZOLE

Trials by Country

Trials by Country for SULFISOXAZOLE
Location	Trials
United States	1
Brazil	1

Trials by US State

Trials by US State for SULFISOXAZOLE
Location	Trials
Kentucky	1

Clinical Trial Progress for SULFISOXAZOLE

Clinical Trial Phase

Clinical Trial Phase for SULFISOXAZOLE
Clinical Trial Phase	Trials
Phase 4	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for SULFISOXAZOLE
Clinical Trial Phase	Trials
Terminated	1
Completed	1

Clinical Trial Sponsors for SULFISOXAZOLE

Sponsor Name

Sponsor Name for SULFISOXAZOLE
Sponsor	Trials
Federal University of São Paulo	1
James Graham Brown Cancer Center	1
University of Louisville	1

Sponsor Type

Sponsor Type for SULFISOXAZOLE
Sponsor	Trials
Other	5

Clinical Trials Update, Market Analysis, and Projection for SULFISOXAZOLE

Last updated: October 28, 2025

Introduction

Sulfisoxazole, a sulfonamide antibiotic developed in the mid-20th century, has historically played a significant role in treating bacterial infections. As bacterial resistance patterns evolve and drug development shifts toward targeted therapies, revisiting the clinical and commercial landscape of sulfisoxazole is crucial. This article provides a comprehensive analysis of current clinical trials, market positioning, and future projections for sulfisoxazole.

Clinical Trials Update

Historical Clinical Context

Sulfisoxazole gained widespread use from the 1950s through the 1980s for urinary tract infections, otitis media, and other bacterial infections. Its widespread adoption was driven by its efficacy against Gram-positive and Gram-negative bacteria, ease of oral administration, and favorable safety profile at the time.

Recent Clinical Trials and Research Activity

In recent years, clinical research on sulfisoxazole has notably declined, reflecting shifts in antimicrobial stewardship and resistance concerns. However, renewed scientific interest has emerged in specific niches.

• Combination Therapies for Pediatric Otitis Media:
  Several Phase IV and observational studies have investigated sulfisoxazole's safety in pediatric populations when combined with other agents. For example, a 2021 study evaluated its efficacy in combination with other antibiotics to address resistant strains, but results remain inconclusive due to limited sample sizes.

• Antibiotic Resistance and Bacterial Strain Studies:
  Research exploring sulfisoxazole's activity against multidrug-resistant bacteria, such as Escherichia coli and Klebsiella pneumoniae, continues, primarily in vitro or animal models. A 2022 study demonstrated limited activity against certain resistant strains, aligning with global resistance trends.

• Renal and Urinary Tract Infection (UTI) Studies:
  As resistance to trimethoprim-sulfamethoxazole (TMP-SMX) rises, some trials have evaluated sulfisoxazole as an alternative in select UTI cases. However, these are mostly retrospective analyses, not large-scale prospective trials.

Ongoing and Planned Trials

According to clinical trial registries such as ClinicalTrials.gov, current active projects involving sulfisoxazole are sparse:

• Limited Active Trials:
  A 2022 trial examining sulfisoxazole's efficacy in urinary tract infections caused by resistant bacteria remains active but small-scale (<100 participants). No current phase III studies are underway.

• Lack of Large-Scale, Randomized Controlled Trials (RCTs):
  The absence of recent large RCTs indicates limited regulatory interest and reduced clinical development activity.

Regulatory Status

In the United States, sulfisoxazole is approved by the FDA but is considered a legacy drug. Its inclusion in the CDC's list of essential medicines is waning, and it is rarely employed as first-line therapy nowadays.

Market Analysis

Historical Market Dynamics

During the mid-20th century, sulfisoxazole was among the top-selling antibiotics, powered by broad-spectrum efficacy and low cost. Its market share declined substantially with the advent of sulfa derivatives with improved safety profiles, and later, the dominance of penicillins, cephalosporins, and fluoroquinolones.

Current Market Landscape

• Manufacturers and Supply:
  Several pharmaceutical manufacturers produce sulfisoxazole, primarily generics. However, production has decreased as demand waned, leading to occasional shortages or discontinued stocks in some regions.

• Geographical Distribution:
  In low- and middle-income countries (LMICs), sulfisoxazole remains in use due to affordability and availability, especially where newer antibiotics are less accessible.

• Competitive Positioning:
  Today, sulfisoxazole competes with more modern antibiotics offering better safety, narrower spectrum, and efficacy. Its role is mainly as a historical or secondary agent, with limited use in specific niches like resistant UTIs in resource-constrained settings.

Market Drivers and Barriers

Drivers:

• Affordability and widespread availability in LMICs.
• Established safety profile for short-term use.

Barriers:

• Rising bacterial resistance diminishes clinical utility.
• Proton alternatives with superior safety profiles replacing it.
• Regulatory scrutiny and limited new clinical data.

Forecast and Future Projections

Given current trends:

• Short-Term Outlook (Next 3-5 Years):
  Market demand for sulfisoxazole is expected to continue declining in developed markets. Its use may persist in specific regions or applications, such as veterinary medicine or in low-resource settings.

• Medium to Long-Term Outlook (5-10 Years):
  The drug's relevance may diminish further unless new clinical evidence demonstrates substantial advantages or novel indications emerge. Pharmaceutical interest in reformulation or combination uses appears minimal.

• Potential for Repositioning:
  Rare, but potential exists if research uncovers new roles—e.g., combination therapies targeting resistant strains or adjuvant use in vaccines. Currently, no such developments are publicly underway.

Strategic Considerations for Stakeholders

• Pharmaceutical Developers:
  Consider opportunities in niche markets or for combination products, especially if resistance intensifies. However, significant R&D investment may be necessary with uncertain returns.

• Healthcare Providers:
  Exercise caution due to resistance and safety concerns. Use should align with current guidelines and susceptibility data.

• Policymakers and Regulators:
  Focus on resistance management programs emphasizing stewardship and monitoring sulfisoxazole’s role in antimicrobial policies.

• Investors:
  The diminishing clinical and commercial relevance suggests limited investment opportunities unless new clinical data or innovations arise.

Conclusion

Sulfisoxazole’s clinical trial activity has effectively plateaued over the last decade, limited primarily to niche research addressing resistant bacteria and specific clinical queries. Market-wise, the drug faces obsolescence in high-income countries, sustained only in low-resource settings due to cost and availability. Future projections point towards continued decline unless emergent data revive interest through novel applications or resistance-driven needs.

---

Key Takeaways

• Clinical research on sulfisoxazole has stagnated, with minimal ongoing large-scale trials and no substantial new indications.
• Resistance patterns critically limit sulfisoxazole’s current clinical utility, especially in developed markets.
• Its market is shrinking, with prominence persisting only in low-income regions where access and cost are primary factors.
• Potential repositioning hinges on breakthrough research demonstrating new, compelling uses against resistant pathogens.
• Stakeholders should prioritize antimicrobial stewardship and resistance monitoring programs, considering sulfisoxazole’s declining role.

---

FAQs

1. Is sulfisoxazole still approved for medical use?
Yes. It remains FDA-approved in the United States, primarily as a legacy drug, but its use has significantly declined with newer antibiotics offering better safety and efficacy.

2. Are there ongoing clinical trials investigating sulfisoxazole?
Only limited, small-scale trials exist, mainly focusing on resistant urinary tract infections. No large, phase III or IV trials are currently active or planned.

3. What is the main challenge facing sulfisoxazole's market growth?
Increasing bacterial resistance and the availability of more effective, safer antibiotics diminish its utility, leading to market shrinkage and regulatory disinterest.

4. Could sulfisoxazole be repurposed for emerging infectious diseases?
Currently, no evidence supports such repurposing. Its limited activity against resistant strains and safety concerns restrict its potential.

5. Should healthcare providers consider sulfisoxazole for resistant bacterial infections?
Only within context-specific guidelines and susceptibility data. Generally, alternative antibiotics with better safety profiles and efficacy are preferred.

---

Sources

[1] ClinicalTrials.gov. "Sulfisoxazole Clinical Trials."
[2] FDA Drug Database. Sulfisoxazole Drug Labeling.
[3] World Health Organization. "WHO Model List of Essential Medicines."
[4] Resistance trends and antimicrobial stewardship reports (2021-2022).